Executives
Cynthia Clayton - Vice President, Investor Relations and Corporate Communications
John Maraganore - Chief Executive Officer and Director
Barry Greene - President and Chief Operating Officer
Akshay Vaishnaw - Senior Vice President and Chief Medical Officer
Analysts
Geoff Meacham - JPMorgan
Alethia Young - Deutsche Bank
Marko Kozul - Leerink Swann
Alan Carr - Needham & Company
Ted Tenthoff - Piper Jaffray
Stephen Willey - Stifel
Alnylam Pharmaceuticals, Inc. (ALNY) ALN-TTRsc Phase I Clinical Data Conference Call September 23, 2013 8:00 AM ET
Operator
Welcome to the Alnylam Pharmaceuticals conference call to discuss interim clinical results from their ALN-TTRsc Phase I trial. (Operator Instructions) I would now like to turn the call over to the company.
Cynthia Clayton
Good morning, everyone. I am Cynthia Clayton, Vice President of Investor Relations and Corporate Communications at Alnylam. On the call with me today are John Maraganore, our Chief Executive Officer; Barry Greene, President and Chief Operating Officer; and Akshay Vaishnaw, Executive Vice President and Chief Medical Officer.
For those of you participating via conference call, the slides we have made available via webcast can also be accessed by going to the Investors page of our website, www.alnylam.com.
During today's call, as outlined on Slide 2, John will provide some context on our ALN-TTRsc clinical results and what they mean for the program Alnylam and for the RNAi field. Akshay, who is on the call remotely, will then review the results of the ALN-TTRsc clinical study. Barry will review our upcoming milestones, and we will then turn the call over to you for your questions.
Before we begin, and as you can see on Slide 3, I'd like to remind you that this call will contain remarks containing Alnylam's future expectations, plans and prospects, which constitute forward-looking statements for the purposes of the Safe Harbor provision under the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including those discussed in our most recent quarterly Report on file with the SEC.
In addition, any forward-looking statements represent our views only as of the date of this recording, and should not be relied upon as representing our views as of any subsequent date. We specifically disclaim any obligations to update such statements.
I will now turn the call over to John.
John Maraganore
Thanks, Cynthia. Welcome, everyone, and thanks for joining us this morning. As you can imagine, we are very excited to share with you these positive clinical data from our ALN-TTR subcu Phase I study.
These human data are the first to be presented for our proprietary GalNAc-siRNA conjugate delivery platform, which enables subcutaneous dosing of RNAi therapeutics with a wide therapeutic index. These new clinical results clearly establish human translation for RNAi therapeutics that utilizes delivery platform.
Moreover, we believe these new results demonstrate an unmatched level of efficacy for RNA therapeutics with a consistent approximately 90% target gene knockdown via subcu dose administration, in addition to a very promising safety profile. More specifically to our TTR amyloidosis program, we believe these results establish a new benchmark for consistent and sustained TTR knockdown of approximately 90% for RNA therapeutics in development for ATTR.
Because of results like these, our GalNAc-siRNA conjugate delivery platform has now become our primary approach for execution on our Alnylam 5x15 product strategy and in addition to our TTR cardiomyopathy program, it is the platform we're using in our programs in hemophilia, porphyria, complement-mediated diseases, hypercholesterolemia, beta-thalassemia and alpha-1-antitrypsin deficiency, amongst others programs that are yet to be disclosed.
As a result, these data are very meaningful, not only for the continued advancement of ALN-TTRsc, but also for the continued execution on our entire Alnylam 5x15 product strategy. Through this strategy, we believe that we are building a compelling opportunity for shareholder value creation with a modular and reproducible approach for development and ultimately commercialization of innovative medicines for genetically defined disease.
We are in the midst of very exciting times at Alnylam with a steady flow of free clinical and clinical data. And these new results reflect the strong potential of RNAi therapeutics to become a whole new class of innovative medicines.
I'll now turn the call over to Akshay, for a more detailed review of the data. Akshay?
Akshay Vaishnaw
Thanks, John. As you just heard, these new ALN-TTRsc results represent a major milestone in our ATTR program as well as our entire pipeline of RNAi therapeutics. We believe this level of consistent TTR knockdown is exceptional and unmatched. And we now aim to advance ALN-TTRsc in future clinical studies with the goal of achieving approximately 90% TTR knockdown to maximize clinical efficacy.
As most of you are aware, our ATTR program is our lead 5x15 program. ATTR is a devastating, often fatal, hereditary orphan disease caused by mutations in TTR gene afflicting approximately 50,000 people worldwide.
There are two clinical presentations of ATTR. These include familial amyloidotic polyneuropathy or FAP, which affects approximately 10,000 people globally; and familial amyloidotic cardiomyopathy or FAC, which affects at least 40,000 people worldwide. Of course many patients also show evidence of mixed nerve and heart involvement.
New therapies are clearly needed for the treatment of ATTR, and we believe that our mechanism of action, silencing of the disease causing TTR gene leading to knockdown of the circulating pathogenic TTR protein has the potential to generate a profound therapeutic impact.
Now let me walk you through our ALN-TTRsc Phase I study and the results we have generated to date. As you can see over Slide 10, the Phase I trial is being conducted in the U.K. as a randomized, double-blind, placebo-controlled, single and multi-dose, dose-escalation study, enrolling up to 40 healthy volunteer subjects. The primary objective of the study is to evaluate the safety and tolerability of single and multiple doses of subcutaneously administered ALN-TTRsc.
Secondary objective include assessment of clinical activity of the drug as measured by serum TTR levels. In an initial single-ascending dose phase of the study, subjects receive subcutaneous doses of placebo or ALN-TTRsc from 1.25 mg to 10 mg/kg. In the multiple-ascending dose phase of the study, subjects receive 10 subcutaneous doses of placebo or ALN-TTRsc from 2.5 mg to 10 mg/kg.
As you can see on the Slide 11, interim data from the 28 subjects enrolled and analyzed in this study to date, showed that single and multiple dose administration of ALN-TTRsc resulted in rapid, dose-dependent, consistent and durable knockdown of serum TTR levels.
In the multi-dose cohorts, there was a statistically significant knockdown of serum TTR at all doses tested as compared to placebo. At a dose of 5 mg/kg, ALN-TTRsc administration resulted in up to 93.3% knockdown of serum TTR and a mean TTR knockdown of 87.5% at nadir. At a dose of 10 mg/kg, ALN-TTRsc led to up to 94% knockdown of serum TTR and a mean TTR knockdown of 92.4% at nadir.
By all accounts, this is an exceptional and unmatched level of TTR knockdown. Notably, during the period of dose administration, TTR levels are essentially clamped down showing a very consistent effect during dosing. In addition, we are very pleased to see a very rapid onset of action, with nadir achieved at about day 50, and then a very durable effect after cessation of drug with recovery to baseline levels at several weeks after.
And on the inside of Slide 11, analysis of TTR knockdown in humans as compared to non-human primates shows there's a highly correlated effect between the two species on a milligram per kilogram basis. Importantly, as John said, we believe these results unambiguously confirm human translation for our GalNAc-siRNA conjugate platform.
Now, our Phase I study is ongoing and we're currently enrolling subjects in additional cohorts to explore the activity of ALN-TTRsc administered weekly at a dose of 7.5 mg/kg as well as administration of ALN-TTRsc on once every two week dosing schedule. We'll use these additional data to finalize our dose and dose regimen selection for the start of our Phase II later this year with the start of our Phase III plan for next year, but we expect to be proceeding with either a 5 mg/kg or 7.5 mg/kg weekly or once a week two-week dosing regimen.
Setting up safety in this study, as reported to date, single and multiple doses of ALN-TTRsc were found to be generally safe and well tolerated. There were no significant or serious adverse events associated with the drug at doses through 10 mg/kg.
As detailed on Slide 12, all adverse events would be mild or moderate in severity. Injection site reactions were observed in the minority of subjects, including those receiving placebo. These are reported as being clinically mild and consist of transient erythema associated in minority of cases with edema or pain.
In all cases, these reactions were self-limiting and results completely typically within two hours of onset. Importantly there were no study discontinuations, flu-like symptoms or changes in cytokine, CRP, liver function test or kidney function or hematologic parameters.
In aggregate, these new data support our conviction that ALN-TTR has the potential to be an important therapeutic for the treatment of familial amyloidotic cardiomyopathy, a disease for which there are no approved therapies. Clearly, the ability of RNAi therapeutic to achieve a consistent approximately 90% knockdown of serum TTR sets a new benchmark that I believe has the potential to translate into meaningful clinical benefit for patients.
With these results in hand, we are well-positioned for continued execution on this program, which includes the initiation of a pilot Phase II study in FAC patients by the end of this year, and assuming positive results start of a pivotal Phase III trial with ALN-TTRsc by the end of 2014.
And with that, I'd like to turn the call over to Barry. Barry?
Barry Greene
Thanks, Akshay, and good morning, everyone. As you've heard we are demonstrating with robust human clinical data that the RNAi pathway can be harnessed to create high-impact innovative medicines. These new data point out our GalNAc-siRNA conjugate delivery platform as our primary approach for execution on our Alnylam 5x15 product strategy.
As a result, these data are very meaningful, not only for the continued advancement for ALN-TTRsc, but also for the continued execution of our entire Alnylam 5x15 product strategy. And while we have made tremendous progress since the start of the year, we still have some very exciting preclinical and clinical data presentations and milestones coming out of the rest to the year, as you can see on Slide 16.
As Akshay mentioned, we remain on track to start a Phase II study with ALN-TTRsc in cardiomyopathy patients later this year and are planning to start a Phase III trial in 2014. Now, with regard to our TTR02 program, we expect to present further data from our Phase II trial at the International Symposium on FAP in Brazil in November. These data will include full TTR knockdown data for about 30 ATTR patients.
For patients enrolled in Phase II study, we aim to begin an open-label extension study as well in the coming weeks. This study will include clinical data that will begin to readout in 2014.
Finally, we plan to initiative a Phase III pivotal trial for ALN-TTR02 in polyneuropathy patients by the end of the year. Without a doubt, this continues an exciting transition for Alnylam, as we enter advanced stages of our clinical development with our lead program.
Now, turning to our ALN-AT3 program for hemophilia, we've also made tremendous progress and are on track to file an IND for this program in the fourth quarter of this year and a Phase I start in early 2014. With our ALN-AS1 porphyria program we expect to identify a final development candidate for the program by late 2013 and to advance into clinic in 2014.
We also plan to nominate a development candidate for our ALN-CC5 program for complement-mediated diseases by the end of this year. For ALN-CC5, we'll provide clinical timeline guidance at the beginning of next year, but you can expect us to move this program forward quickly. And we plan to end the year with greater than $320 million cash.
Finally, with a number of scientific meetings from now to the end of the year, where our scientists will be presenting new data from essentially all of our 5x15 programs. In summary, I think it's clear that we are executing on our goal of advancing RNAi therapeutics with a potential to become an entirely new class of innovative, high-impact medicines for patients in need.
With that, I'd like to turn the call back over to the operator for your questions. Ellie, we'll take questions now.
Question-and-Answer Session
Operator
(Operator Instructions) Our first question comes from Geoff Meacham of JPMorgan.
Geoff Meacham - JPMorgan
I had a few questions. I knew you guys hadn't reported ISRs with the IV formulation, at least I don't remember that, but you have that here. Do you think that for subcu, this is the administration itself or is it some mechanism for the GalNAc delivery or is this problematic at all when you guys look at taking subcu into Phase III down the road? And I have one follow-up.
John Maraganore
Geoff, as you know, just about every subcutaneously-delivered drug has injection site reactions as a reported AE that true with HUMIRA, it's true with insulin, it's true with low-molecular-weight heparin. So it is very much a common phenomenon with subcutaneously-delivered drugs.
With an intravenous infusion of course, there you don't typically have these type of reactions, because you go to a hospital, you get an intravenous catheter administered. So it's a very different type of procedure. None of these injections site reactions that we're seeing are in any way, shape or form limiting, in terms of how we think about that. And the drug will be forward. Akshay, do you want to comment any further on that.
Akshay Vaishnaw
Yes, and I think couple of things over that is that as we described these reactions are very transient, lasting a couple of hours and this consist generally of redness. And importantly no one discontinued, no one was bothered by them, no. Action needed to be taken. And so they are very much, as John is saying, in keeping with other subcu drugs, which have been very successful. And in an indication like this we see nothing but green lights with these great data that we have to knockdown up to almost 94%.
Geoff Meacham - JPMorgan
And then the follow-up is for ATCR. From you guys, epidemiology work, are the mutations at the, let's say the less or more severe spectrum of disease that you can use to inform the entry criteria, when you guys look to start your pivotal later on this year?
John Maraganore
Yes, that's a great question. Akshay, do you want to handle that?
Akshay Vaishnaw
Geoff, just repeat that. I didn't quite get the angle on your question. Are the mutations less or more severe?
Geoff Meacham - JPMorgan
At the spectrum that you can somehow narrow the population or inform your entry criteria for the pivotal study.
Akshay Vaishnaw
I mean the genotype/phenotype relationships are pretty well understood, Geoff. And so we are fortunate to have a loss of literature and through our network of KOLs that we work within the FAC space. The kind of lion's share of FAC in the U.S. is taken out by this mutation V122I, which is dominant in the African-American population. And then there is T60A, and then there are about four others that are associated with FAC. So there's about half-a-dozen mutations that are well described, and we'll inform the design of our Phase III study.
John Maraganore
And Geoff, I'll just add, that in the Phase II that we're about to start, we'll look at a range of different genotypes in that study. It's not going to be restricted to any given genotype. So that will give us some experience across different genotypes prior to starting Phase III.
Operator
Our next question comes from Alethia Young of Deutsche Bank.
Alethia Young - Deutsche Bank
Just a question on like, in the open-label extension study, are you guys planning on communicating like different points with FDA about your progress there or is there any opportunity for breakthrough or faster pathway to approval?
John Maraganore
Alethia, that's a great question. We'll obviously keep the close touch with the FDA if there are compelling clinical data, we certainly will consider it. We'll go to the FDA and talking about our breakthrough, but we have to see how the data merge. Clearly that study is going to start very soon. There will be clinical endpoint data that we read out.
Theoretically, we'll going to give you some more guidance on that when we start that study. But there will be frequent, let me not use the word frequent, there will be periodic reviews of data that come out of that and obviously that's going to help our overall accrual efforts. In our TTR02 Phase III effort, it will obviously been meaningful for physicians to also see how that's progressing. And we'll certainly look at those data in the context of our interactions with the FDA. Akshay, anything you do you want to add to that.
Akshay Vaishnaw
No, no, I think that's exactly right. That's exactly right. We are excited to get the study going and we start to getting paid.
Alethia Young - Deutsche Bank
I hope you don't mind, just one follow-up. The three doses for the next three cohorts, can you just tell me what they are again, please?
John Maraganore
You mean the additional cohorts in the phase, the current Phase I.
Alethia Young - Deutsche Bank
Yes.
John Maraganore
So we are looking at a couple of things really. One, is we wanted to explore 7.5 mg/kg dose in that which is intermediate between the 5 and 10. And anything that we want to explore is in every other week dosing regimens. If you look at our data in our presentation from the multi-dose kinetics, you will see that the levels are very suppressed, and they seem after dosing has stop to be quite durable and it does open up the question of whether or not we can also explore once every two week dosing subcutaneously with our drug.
So we want to explore that in these additional cohorts. And I believe the additional cohort that's there is just a bulk of numbers in the overall population, so it's sort of in the same context of what's right there. Akshay, anything to add to that.
Akshay Vaishnaw
No, no, I think that's right. These initial interim data given there is a lot of guidance on different doses of regimen we'll explore. And I think it will be exciting to do that over the next couple of months.
Operator
Our next question comes from Marko Kozul of Leerink Swann.
Marko Kozul - Leerink Swann
I'd also like to echo my congratulations on your continued progress. My first question has to do with efficacy of GalNAc as a delivery platform. Can you give us a preview of where you might be headed in terms of further improvements and refinements? I think in this current Phase I TTR subcu multi-dose experience, you dosed up to 10 mg/kg.
And back in 2012 at OTS and on Slide 5, I think of your presentation this morning you appear to be achieving meaningful knockdown in the 2 to 3 mg/kg range for AT3 and PCS in pre-clinical models. So can you give us a preview of further improvements on where you might be headed?
John Maraganore
Yes. Thanks, Marko, that's a great question. The ALN-TTR subcu is the first GalNAc conjugate that we took into development. And obviously, we've now seen some very exciting and impressive results. But as all things in science, with a vibrant research group like we have here, there are constant improvements that we're making in these platforms and if that -- the benefit of that has been accrued in programs like our PCSK-9 program and our AT3 program as highlighted on Slide 5 of the conference call deck.
And you can clearly see that we're achieving ED80 type knockdown at doses around 1 milligram per kilogram. So it's about a tenfold, almost a tenfold, maybe a little bit less than a tenfold improvement compared to ALN-TTRsc. So we expect with AT3, which is about to start our clinical testing. We expect to be seeing 80% knockdown levels and doses that are in the 0.5 to 0.75 mg/kg level, which is really quite impressive. And we would expect to see similar type of effects with other GalNAc conjugates in the future.
So just exciting progress in general, and obviously the other thing, Marko, I will say is when we look at non-human primate data now with our GalNAc conjugates like we presented ISTH for our antithrombin program. We now know that that's one-to-one correlation in humans, based on the data you've seen today. So it's very exciting to able to have the confidence around that translation. And we just expect that to continue.
Marko Kozul - Leerink Swann
And just a quick second question that has to do with safety, which appears pretty clean in the poster and slides this morning. When you have final results from this Phase I study, what additional safety info will we have?
John Maraganore
Marko, we'll just have additional patients to look at and obviously look at that in the totality of the existing data sets. But I think also we'll soon be patients with this drug. And we'll soon be generating additional data, both efficacy and safety in patient populations and you will be seeing some of those data next year.
Operator
Our next question comes from Alan Carr of Needham & Company.
Alan Carr - Needham & Company
One of them, can you give us an update on -- any update on regulatory discussions around the upcoming Phase III trial? And then also, I guess a bigger picture question around the safety database here, how many patients have you been in with IV and subcutaneous across each of these some different platforms? And then the third one to follow-up on a previous question, it looks like you're doing, if you got three more cohorts, is it 7.5 every week? And then the other two are 5 and 7.5 every other week?
John Maraganore
Let me answer the first one or the last one first, which is its 7.5 mg/kg in two cohorts weekly and then there is an additional cohort of 7.5 mg/kg every other week, is the current lineup of what we're doing into Phase I. And again those data, we'll likely present those data or report on those data some time next year.
But as it relates to the first question on the regulatory discussions for TTR02, I can tell you that they are extremely well. We're pleased with the feedback we've gotten thus far. We don't foresee any issue from where we stand today, in terms of how we will proceed with the protocol and stay tuned on final details of the design, when we're going to report on them. But I think that we're quite pleased with those discussions. Akshay, anything to add on that point.
Akshay Vaishnaw
No, I think that's exactly right.
John Maraganore
And then you're challenging me now on the second question to sort of actuarially come together with numbers for you. So let me give you top-of-mind numbers. Our TTRO2 Phase I study was around 19 patients as I recall the number and our TTRO2 Phase II study that's going to be presented -- the final results will be presented in November, is about 30 patients. Our TTR subcu Phase I study that we presented today is 28 subjects. And obviously by the end of the additional cohorts it will be an additional -- Akshay help me out here.
Akshay Vaishnaw
No, I was just going to jump in, John. When we did R&D Day in July and added up the numbers, then at that point we had about 175 patients and the subject exposed in a various systemic deliveries human studies that we've done, so from our liver cancer program, TTRO1, TTRO2, PCS and others. And so John was giving you individual numbers from some of those studies, but at that number will soon to approach to 100.
We've given over 500 doses of intravenous Lipid nanoparticle based drug over two years of dosing. And in this current TTRsc study we'll of course top-out at around 40 individual exposed. So we're getting to a significant database and as we progressively shared the safety and efficacy information, obviously we're excited about the profile emerging for our drugs, both IV and LMP from a safety and efficacy viewpoint.
Operator
Our next question comes from Ted Tenthoff of Piper Jaffray
Ted Tenthoff - Piper Jaffray
So I guess my question sort of gets back to sort of a higher level, and I love the fact that you have the optionality around the IV and subcu and are now entering into FAC as well. But maybe tell us a little bit about how you see the future treatment of FAP. And obviously this is going to be data-driven, but is this a disease where maybe less-severe patients will be treated with subcu or maybe patients will be on-boarded first with IV to get disease under control? With this really impressive subcu data, are we even going to need an IV dose? I mean I know this is probably a little bit early to be looking into the crystal ball, but how do you foresee ultimately treating this disease, which is probably more heterogeneous than most people realize?
John Maraganore
It's a great question. Barry you want to handle it.
Barry Greene
Ted thanks for the question and the crystal ball into the future. It's fun to think about the issue of having two commercially available drugs for these patients. And as you know, our plan is develop ALN-TTR02 for FAP and ALN-TTRsc for the cardiomyopathy patients, FAC.
As we think about due to two commercial products available for all ATTR programs, it's likely in the future that we will generate data that allows these products to be used in the future interchangeably. With good data that allows us to educate the physician population to the appropriate use perfect dose and frequency of the drugs.
From a pharmacoeconomic perspective the diseases allow the kind of orphan pricings that you expect, so it won't be any economic incentive to change paces from one to the other, it really will be what's best for a patient. And as you fully appreciate in the world of orphan diseases, once we have and are benefiting the patient with the treatment of our drugs, we want to keep them on our therapies for the rest of their lives.
John Maraganore
And just to add to that, Ted, I suspect that in the future some patients will have to continue receiving drugs intravenous infusion. Like to go to the hospitals, with their physician to receive drug, and then other patients will say, well, I like the concept of having a at-home subcu option, and that's what I'd like to do going forward. And so I think we're going to create optionality here for patients in the future. And obviously, most importantly have what really is the best-in-class program, and best-in-class therapies available for these patients.
Ted Tenthoff - Piper Jaffray
I think there's a lot to learn, but I think you guys are making great progress, so really exciting.
Operator
Our final question comes from Stephen Willey of Stifel.
Stephen Willey - Stifel
I may have missed this, but just to confirm, the 7.5 mg/kg dose that you are planning to use in these next couple of cohorts, that's a single subcu injection, correct?
John Maraganore
Correct.
Stephen Willey - Stifel
And I know you also looked at retinal binding in vitamin A. Just any color around that? Is that consistent with what we have seen?
John Maraganore
Just totally beautifully consistent with what we've reported before. There is just a one beautiful correlation between [ph] RVT and vitamin A knocks down with TTR knockdown as well. So Steve, let me just also provide one clarification point. So we are doing 7.5 mg/kg weekly, okay. But we do, because of volume of administration we are using two injections to achieve that dose.
Stephen Willey - Stifel
And the volume, it's associated with each injection?
John Maraganore
It's roughly 1.5 ml for each injection of that dose. And so at 5 mg/kg, it could be done as a single 2 ml injection in that case.
Operator
And with no further questions, I would like to turn the conference back over to John, for any closing remarks.
John Maraganore
Well, thanks everyone for joining us this morning. We're obviously very excited about the new data and the potential for the continued execution of this platform in our Alnylam 5x15 strategy. And we look forward to sharing more updates and there will be more updates with you in the weeks and months to come. So thank you very much. Bye, bye now.
Operator
Ladies and gentlemen, this does concludes today's conference. You may now disconnect and have a wonderful day.
Copyright policy: All transcripts on this site are the copyright of Seeking Alpha. However, we view them as an important resource for bloggers and journalists, and are excited to contribute to the democratization of financial information on the Internet. (Until now investors have had to pay thousands of dollars in subscription fees for transcripts.) So our reproduction policy is as follows: You may quote up to 400 words of any transcript on the condition that you attribute the transcript to Seeking Alpha and either link to the original transcript or to www.SeekingAlpha.com. All other use is prohibited.
THE INFORMATION CONTAINED HERE IS A TEXTUAL REPRESENTATION OF THE APPLICABLE COMPANY'S CONFERENCE CALL, CONFERENCE PRESENTATION OR OTHER AUDIO PRESENTATION, AND WHILE EFFORTS ARE MADE TO PROVIDE AN ACCURATE TRANSCRIPTION, THERE MAY BE MATERIAL ERRORS, OMISSIONS, OR INACCURACIES IN THE REPORTING OF THE SUBSTANCE OF THE AUDIO PRESENTATIONS. IN NO WAY DOES SEEKING ALPHA ASSUME ANY RESPONSIBILITY FOR ANY INVESTMENT OR OTHER DECISIONS MADE BASED UPON THE INFORMATION PROVIDED ON THIS WEB SITE OR IN ANY TRANSCRIPT. USERS ARE ADVISED TO REVIEW THE APPLICABLE COMPANY'S AUDIO PRESENTATION ITSELF AND THE APPLICABLE COMPANY'S SEC FILINGS BEFORE MAKING ANY INVESTMENT OR OTHER DECISIONS.
If you have any additional questions about our online transcripts, please contact us at: transcripts@seekingalpha.com. Thank you!
No comments:
Post a Comment